Endologix is recalling all of its AFX endovascular abdominal aortic aneurysm (AAA) systems after continued reports of type III endoleaks. The US Food and Drug Administration (FDA) has identified this ...
The US Food and Drug Administration has identified this as a Class I recall, with continued device use resulting in serious injury or death. Endologix has issued a device recall for the AFX ...
Endologix ® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received notice that the U.S. Food and Drug Administration (FDA) ...
The US Food and Drug Administration (FDA) has issued a MedWatch recall notice for all AFX Endovascular AAA Systems by Endologix following a voluntary recall action by the company in July. The notice, ...
Dr. Matt Thompson, Chief Medical Officer of Endologix Inc. commented, “On September 28, 2017, the FDA issued a letter to health care professionals (“HCPs”) regarding Type III endoleaks after ...
The US Food and Drug Administration (FDA) is reminding clinicians about the need for "at least yearly, lifelong follow-up" to monitor for type III endoleaks in patients with any type of Endologix AFX ...
Shares of Endologix (NASDAQ: ELGX) were down 37% on Friday after the medical device maker announced disappointing earnings at market close on Thursday. Specifically, revenue decreased 7.9% year over ...
Shares of Endologix Inc. tumbled 15% Tuesday, as analysts weighed in on the news that the company was placing a temporary shipping hold on its AFX device because of manufacturing issues. Analysts at ...
IRVINE, Calif.--(BUSINESS WIRE)--Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received notice that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results